Phase I – Other

1,064 trials 249 recruiting

Filter these 1,064 trials by condition, country, sponsor and more.

Open in Search →

A study to test how well different doses of BI 764532 are tolerated by people with a tumour in the brain that is positive for DLL3 Ended

2022-501766-22-01 Glioma expressing DLL3 2024-04-23
A study to assess the safety, tolerability, uptake and efficacy of VMX-C001 in healthy volunteers. Ended

2023-507059-32-00 To restore coagulation in patients taking DOACs who are 2024-02-21
Study to measure filgotinib in the blood of children and teenagers with arthritis taking filgotinib-GLPG0634-CL-131 Ended

2023-505844-21-00 juvenile idiopathic arthritis 2024-02-14
DAREONTM-9: A study to test how well different doses of BI 764532 are tolerated by people with small cell lung cancer when taken together w… Ended

2023-506007-26-00 relapsed/refractory extensive stage - small cell lung c 2024-01-15
DAREON™-7: A study to test how well different doses of BI 764532 in addition to chemotherapy are tolerated by people with advanced neuroendo… Ended

2023-505870-13-00 Extra-pulmonary neuroendocrine carcinoma (epNEC) 2024-01-11
DAREON™-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small… Ended

2023-506008-20-00 Extensive-stage small cell lung carcinoma (ES-SCLC) 2024-01-11
An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative… Ended

2024-511963-28-00 Neoadjuvant therapy in locally-advanced rectal cancer 2023-12-19
Study of safety, tolerability and efficacy of DFV890 in adult participants with myeloid diseases Ended

2022-501406-36-00 Myeloid disease 2023-12-14
Phase I study evaluating the safety and efficacy of MEDI5752 in combination with stereotactic radiotherapy in patients with metastatic sarco… Ended

2024-515551-38-00 Metastatic soft tissue sarcoma 2023-12-12
A trial to examine the biological effects of Saruparib (AZD5305) alone, Darolutamide alone, and in combination in patients with newly diagno… Ended

2023-503691-25-00 Newly diagnosed prostate cancer 2023-12-11
CA-4948-104: A Ph1 Study of Emavusertib in AML CR MRD+ Patients Currently Receiving Azacitidine and Venetoclax Ended

2023-505828-58-00 Acute Myeloid Leukemia 2023-12-05
Local tolerance and PK/PD assessment of TAR-0520 gel when applied topically in healthy subjects Ended

2023-504178-39-00 Prevention of anticancer therapy adverse reactions 2023-11-09
A Phase 1b study to evaluate the safety, pharmacokinetics, and anti-tumour activity of the Myc inhibitor OMO-103 administered intravenously … Ended

2023-504376-21-00 pancreatic ductal adenocarcinoma 2023-08-28
A study to test different doses of obrixtamig (BI 764532) combined with ezabenlimab in patients with Small Cell Lung Carcinoma and other neu… Ended

2022-502728-30-00 Small Cell Lung Carcinoma expressing DLL3 2023-08-25
A study to evaluate the dose optimization measures and safety of Etentamig (ABBV-383) in subjects with Relapsed or Refractory Multiple Myelo… Ended

2023-504674-38-00 Relapsed or Refractory Multiple Myeloma 2023-07-31
Neoadjuvant ADT with TULSA Ended

2022-502067-38-00 Intermediate-risk prostate cancer 2023-06-29
Long-Term Follow-Up (LTFU) for Gene Therapy of Pyruvate Kinase Deficiency (PKD): A Phase I Clinical Trial to Evaluate the Safety of the Infu… Ended

2022-501526-38-00 Pyruvate kinase deficiency 2023-06-06
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants Ended

2024-514004-14-00 Alzheimer’s Disease 2023-02-23
A MultIceNTER Phase I Peptide VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3-Mutated Gliomas – (INTERCEPT H3) Ended

2024-514840-97-00 glioma WHO grade IV (C71.1-9 according to ICD-10 classi 2023-02-15
Phase 1b study investigating the association of NP137 with Atezolizumab-Bevacizumab combination in first line in unresectable hepatocellular… Ended

2022-500903-38-00 unresectable hepatocellular carcinoma 2023-02-09
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety tolerability, pharmacokinetics… Ended

2023-510061-10-00 Clear cell renal cell carcinoma (ccRCC, first-, second- 2023-01-09
A pilot open label phase I trial to evaluate the safety and the tolerability of a combination of two HIV-1 inducers in HIV+ sub-type B patie… Ended

2024-518141-13-00 HIV 2022-12-05
A phase I trial of IMA970A plus Montanide in combination with Durvalumab (anti-PD-L1) in patients with very early, early and intermediate st… Ended

2024-518298-33-00 Hepatocellular carcinoma 2022-11-21
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis from Gastrointestinal cancer: a phase I study. Ended

2023-509135-17-00 Patients with advanced, irresectable peritoneal metasta 2022-11-18